EIT Pharma to Sponsor and Present at the 2026 Delta Cure International Meeting

KIRKLAND, Wash., Oct. 13, 2026 /PRNewswire/ -- EIT Pharma, Inc. ("EIT Pharma" or the "Company"), a biotechnology company focused on developing therapies for infectious diseases, today announced it will sponsor and present at the 5^th Edition of the Delta Cure International Meeting to be held on October 15-16, 2026, in Milan, Italy.

Delta Cure is recognized as the leading international forum dedicated to Hepatitis Delta Virus and its programming features a comprehensive exploration of the virus, epidemiology, virology, immunology, clinical progression, and effect of therapy on long-term complications. EIT Pharma will present new analyses from the lonafarnib development program for Chronic Hepatitis Delta (CHD). Lonafarnib is currently the only late-stage investigational therapy for CHD with an oral route of administration.

EIT Pharma's Delta Cure International Meeting 2026 Presentation Details:

Oral Presentation:
Title: Histologic improvement and reduction in necroinflammation with lonafarnib-based therapy in chronic Hepatitis Delta: phase 3 D-LIVR trial
Presenter: Dr. Nancy Reau, Associate Director of Solid Organ Transplantation and Section Chief of Hepatology at Rush University Medical Center
Date: Friday, October 16, 2026, 12:00pm CEST
Poster: 104

Breakfast Briefing:
Title: Sunrise on Lonafarnib: EIT Pharma Breakfast Briefing
Date: Friday, October 16, 2026, 7:00am CEST

Poster Presentations:

• Poster 105: Post-treatment response following 48 weeks of lonafarnib therapy: analysis of 24-week follow-up in the phase 3 D-LIVR trial in chronic hepatitis delta; presented by Dr. Saeed Hamid
• Poster 106: Clinical significance of ALT dynamics following lonafarnib treatment cessation in the phase 3 D-LIVR trial; presented by Dr. Ohad Etzion

Earlier this year, the U.S. Food and Drug Administration (FDA) accepted the New Drug Application for lonafarnib for the treatment of CHD, a serious life-threatening liver disease caused by hepatitis D virus in individuals who already have hepatitis B virus infection.

About Lonafarnib
Lonafarnib is an investigational oral therapy candidate being evaluated for the treatment of chronic hepatitis D. Lonafarnib is designed to target a key step in the hepatitis D virus lifecycle and is currently the only oral therapeutic candidate in late-stage clinical development for chronic hepatitis D. Lonafarnib has not been approved by the U.S. Food and Drug Administration or any other regulatory authority for the treatment of chronic hepatitis D. The safety and efficacy of lonafarnib have not been established.

About EIT Pharma, Inc.
EIT Pharma is a biotechnology company focused on advancing therapies for infectious diseases with significant unmet medical needs. The company is developing a portfolio of programs designed to address serious infectious diseases through rigorous science, disciplined execution, and a patient-centered approach focused on translating scientific innovation into meaningful real-world impact for patients.

Forward-Looking Statements
This press release contains forward-looking statements regarding regulatory review timelines, anticipated milestones, potential product characteristics, and future development plans. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Lonafarnib is an investigational product candidate and has not been approved by the FDA. There can be no assurance that the FDA will approve the NDA or that the product will become commercially available. EIT Pharma undertakes no obligation to update forward-looking statements except as required by law.

Media Contact

Reevemark
Jacqueline Zuhse/Jill Steinman
[email protected]
212-433-4600

SOURCE EIT Pharma